Paris—Dentons advised Bpifrance Large Venture on the extension of the Series B fundraising by French biotech company DNA Script, which raised nearly €46 million.

Bpifrance Large Venture is a French fund dedicated to high-potential technology companies. Alongside Bpifrance, Illumina Ventures, Merck Ventures, Life Sciences Partners (LSP) and Danaher Life Sciences Partners are also reinvesting in this fundraising; Casdin Capital, Agilent and Alexandria Real Estate are entering the company in this round.

The proceeds of this fundraising will allow DNA Script to strengthen its workforce to accelerate research and development of new products and to prepare the marketing of its DNA sequencing printer in the US and European markets.

Founded in 2014, DNA Script is a young French biotech company that produces synthetic DNA using modified natural enzymes, unlike traditional methods that use chemical components.

Bpifrance Large Venture was advised on the legal aspects by partner Olivia Guéguen and associate Laura Godard.

About Dentons

Dentons is the world's largest law firm, connecting talent to the world's challenges and opportunities in more than 75 countries. Dentons' legal and business solutions benefit from deep roots in our communities and award-winning advancements in client service, including Nextlaw, Dentons’ innovation and strategic advisory services. Dentons' polycentric and purpose-driven approach, commitment to inclusion and diversity, and world-class talent challenge the status quo to advance client and community interests in the New Dynamic. www.dentons.com